Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Cholangiocarcinoma (CCA) is a challenging cancer with limited treatment options for advanced stages.
• Fibroblast growth factor receptor (FGFR) alterations, specifically fusions or rearrangements, are key drivers in a subset of CCA.
• Targeted therapies inhibiting FGFR signaling represent a promising approach for these patients.

Purpose of the Study:

• To evaluate the efficacy and safety of futibatinib monotherapy in adults with advanced or metastatic cholangiocarcinoma (CCA) harboring FGFR2 alterations.
• To assess the impact of futibatinib on health-related quality of life (HR-QOL) in this patient population.
• To characterize the safety profile and management of treatment-related adverse events associated with futibatinib.

Main Methods:

• Phase II part (FOENIX-CCA2) of a multinational phase I/II study.
• Treatment with futibatinib 20 mg orally once daily as monotherapy.
• Inclusion of adult patients with locally advanced or metastatic CCA with documented FGFR2 fusion or rearrangement who progressed on prior systemic therapy.

Main Results:

• Futibatinib demonstrated clinically meaningful and durable responses in the studied patient population.
• Sustained health-related quality of life (HR-QOL) was observed.
• Hyperphosphatemia was the most common adverse event, manageable with supportive care and dose adjustments.

Conclusions:

• Futibatinib is a valuable targeted therapy for adults with advanced or metastatic CCA and FGFR2 alterations who have progressed on systemic therapy.
• The drug offers a manageable safety profile, with key toxicities like hyperphosphatemia being effectively managed.
• Futibatinib represents an important treatment option for a patient group with limited therapeutic choices and poor prognosis.